On April 14, DiaSorin announced that Mr Tony Chan is the President of DiaSorin China. He will also serve as the Chairman of the Board of Directors of DiaSorin China.

Eastern Money Choice data shows that as of April 13, 28 listed companies in the medical device category have disclosed their 2022 annual reports, of which 18 companies have achieved year-on-year growth in net profit, accounting for 64.29%.

Evident Corporation announced that it has been acquired by private equity firm Bain Capital Private Equity from Olympus Corporation pursuant to the definitive agreement signed on August 29, 2022.

Sysmex Europe and Cerca Biotech said Monday that they have inked a deal for Sysmex to distribute Cerca's molecular breast cancer assay in 13 European markets.

Stilla Technologies and Atila BioSystems said on Thursday that they will codevelop digital PCR kits for cancer liquid biopsy applications.

On March 29, 2023, Hybribio and MGI Tech signed an agreement to reach strategic cooperation in the direction of high-throughput sequencing platform to expand international market.

Roche Diagnostics and ABL Diagnostics announced on Thursday that they have entered an exclusive agreement for Roche to distribute ABL's assays to South African laboratories.

DiaSorin said on Monday that its full-year 2022 revenues grew 10 percent year over year on "solid performance" across all its businesses.

The signing of this acquisition cooperation is undoubtedly an important development opportunity for both Zybio and Shenzhen Thistory Bio-Medical Company.

On March 21, according to the Qichacha data, the major shareholders of Shenzhen Thistory Bio-Medical Company have been changed from Shenzhen Thistory Bio-medical Management and Consulting Enterprise to Zybio Inc.